Craft
  • Home
  •  / Achilles Therapeutics
Achilles Therapeutics

Achilles Therapeutics

Total Funding

$138.1 M

Achilles Therapeutics Summary

Company summary

Overview
Achilles Therapeutics is a developer of immunotherapies intended to offer therapies to treat cancer. Its immunotherapies harness the immune system to destroy cancer cells that target truncal tumor neo-antigens and flags to the immune system present on the surface of every cancer cell, enabling scientists to target and destroy tumors without harming healthy tissues.
Type
Private
Status
Active
Founded
2016
HQ
London, GB | view all locations
Website
https://achillestx.com/
Cybersecurity rating
Sectors

Key people

  • Iraj Ali

    Iraj Ali, Chief Executive Officer

  • Karl Peggs

    Karl Peggs, Chief Medical Officer

    • Sergio Quezada

      Sergio Quezada, Chief Scientific Officer

    • Robert Coutts

      Robert Coutts, Chief Financial Officer

    Operating MetricsView all

    Manufacturing Space, sq. ft.

    64.2K

    FY, 2020

    Office and Laboratory Space, square feet

    24.6K

    FY, 2020

    Trademarks (US)

    3

    May, 2021

    LocationsView all

    2 locations detected

    • London, England HQ

      United Kingdom

      Bechtel House, 245 Hammersmith Rd, Hammersmith

    • Stevenage, England

      United Kingdom

      Gunnels Wood Rd

    Achilles Therapeutics Financials

    Summary financials

    Net income (FY, 2021)
    ($61.1M)
    Cash (FY, 2021)
    $266.3M
    EBIT (FY, 2021)
    ($64.2M)

    Footer menu